Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk

• DOI: 10.1111/bcpt.13625
• Publication Date: 2021-06-15T07:27:43Z
• Authors: Søren P. Johnsen; Thomas B. Rasmussen; Anne Mette Falsti...; Louise Harboe; Gillian Stynes; Lars Dybro; Morten L. Hansen; Axel Brandes; Erik L. Grove; Anna‐Marie Münster
• Keywords: Lower risk

Effectiveness and safety of long-term anticoagulation treatment are uncertain in venous thromboembolism (VTE) patients at intermediate risk recurrence. We examined the association between beyond 1 year outcomes a Danish nationwide register-based study. VTE recurrence, that is, non-cancer with first-time unprovoked VTE, who started oral within 30 days were alive 365 after index included followed 2007 2015. Exposure was extended (>365 days) or (91-365 treatment. Analyses done using Cox regression on propensity score weighted population. 18 609 7232 (38.9%) receiving Mean duration follow-up 2.6 years. Compared treatment, associated lower recurrent (hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.49-0.65) all-cause mortality (HR 0.81, CI 0.72-0.90) an increased major bleeding 1.87, 1.58-2.22). In conclusion, (predominantly warfarin) real-life settings among However, should be considered.